SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic 
SK Hynix Stock Rebounds as AI Memory Chip Demand Fuels Expansion Plans 
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks 
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
Meta AI Strategy Faces Challenges as Zuckerberg Admits Mistakes in Internal Memo 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement 
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage 
Exxon Mobil Set to Appoint Alex Volkov as Global Trading Chief 
BHP Port Hedland Workers Back Strike Action Amid Pay Dispute 
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions 
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges 
Alibaba Offers $1.5 Billion to Acquire Grocery Delivery Platform Pupu 
Woodside Energy Acquires PetroChina’s Browse Stake, Expands Position in Major Australian Gas Project 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
